
    
      This is a randomized, double-blind, placebo- and active-controlled, ascending-dose, 2-way, 2-
      period, incomplete block, crossover, Phase 1 trial to compare the safety, tolerability, PK
      and PD of 3 single doses of INP105 with the safety, tolerability, PK and PD of 1 dose of
      Zyprexa IM (5 mg) and 1 dose of oral Zyprexa Zydis (10 mg). Randomization for Periods 1 and 2
      will occur for each subject on Day 1.
    
  